Sangamo Therapeutics reported a June 2026 month-end cash balance of $14.38 million, up from $4.86 million at the start of the month. This financial update, part of its ongoing Chapter 11 proceedings, provides investors insight into the biotechnology company's Liquidity and operational burn during its restructuring, signaling Solvency for immediate needs.

Key Highlights

  • Sangamo Therapeutics (NASDAQ: SGMOQ) reported total cash receipts of $10,503,072 for the month of June 2026.
  • The monthly operating report provides a detailed view of Sangamo Therapeutics' asset and Liability structure as of June 30, 2026.
  • This positive movement comes within a period of considerable Volatility for the stock, which has seen an 87.5% gain over the past month.

The filing, dated August 6, 2026, provides detailed operational insights into the company's financial status since its Bankruptcy petition on June 23, 2026, following a Q1 2026 Earnings Per Share of $-0.08, notably missing the $0.01 consensus estimate. The company, which reported $27.59 million in cash and equivalents in its profile, is now managing the complex financial environment of its restructuring under Chapter 11 case number 26-10989.

June Cash Flow and Operational Metrics

Sangamo Therapeutics (NASDAQ: SGMOQ) reported total cash receipts of $10,503,072 for the month of June 2026. These inflows substantially boosted the cash balance, despite total disbursements amounting to $977,931 during the same period. The net effect left the company with a cash balance of $14,382,243 by June 30, 2026, demonstrating improved short-term liquidity within the initial phase of its Chapter 11 proceedings.

From an operational standpoint, the company generated gross income of $108,953 in June. However, this was offset by significant general and administrative expenses of $1,096,018, coupled with other expenses of $918,433 and Depreciation and amortization costs of $58,930. While the cash position improved, the substantial operating loss highlights the ongoing challenge of achieving profitability amid its restructuring efforts.

Financial Position and Liabilities Snapshot

The monthly operating report provides a detailed view of Sangamo Therapeutics' asset and liability structure as of June 30, 2026. The company listed total Assets at $153,087,245, with current assets amounting to $18,185,639. On the liabilities side, total obligations reached $89,151,054.

The overall financial snapshot indicates that while the company possesses significant total assets, the large Volume of prepetition unsecured Debt will likely dominate discussions regarding creditor recovery in the ongoing bankruptcy case.

Trading Dynamics and Market Sentiment

This positive movement comes within a period of considerable volatility for the stock, which has seen an 87.5% gain over the past month. Despite this recent uptick, the company's shares are down 65.9% year-to-date, illustrating the significant impact of its financial challenges and Chapter 11 filing on investor confidence. The stock's 52-week trading range of $0.03 to $0.77 further underscores the wide swings in valuation as the market attempts to price the Equity in a bankruptcy context.

Peer companies like BIOQ, KYNB, and LITS experienced little change today, suggesting that Sangamo's movements are largely company-specific. Such speculative trading dynamics highlight the high risks involved for equity holders, whose recovery is typically junior to all debt classes in a Chapter 11 proceeding.

Outlook and Next Catalysts

As Sangamo Therapeutics continues its Chapter 11 process, investors will closely monitor subsequent financial disclosures. The next key catalyst for investors will be the filing of the company's monthly operating report for July 2026. This upcoming report will provide further insights into the company's liquidity, operational performance, and asset-liability management as it navigates the complexities of its bankruptcy.

These reports offer critical transparency into the company's financial health, indicating its progress toward a potential reorganization or Liquidation plan.

Peers Moving on This News